Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yan Zou is active.

Publication


Featured researches published by Yan Zou.


Journal of Medicinal Chemistry | 2009

N-Aryl-oxazolidin-2-imine Muscle Selective Androgen Receptor Modulators Enhance Potency through Pharmacophore Reorientation

Alexandra A. Nirschl; Yan Zou; Stanley R. Krystek; James C. Sutton; Ligaya M. Simpkins; John A. Lupisella; Joyce E. Kuhns; Ramakrishna Seethala; Rajasree Golla; Paul G. Sleph; Blake C. Beehler; Gary J. Grover; Donald Egan; Aberra Fura; Viral Vyas; Yi-Xin Li; John S. Sack; Kevin Kish; Yongmi An; James A. Bryson; Jack Z. Gougoutas; John D. Dimarco; Robert Zahler; Jacek Ostrowski; Lawrence G. Hamann

A novel selective androgen receptor modulator (SARM) scaffold was discovered as a byproduct obtained during synthesis of our earlier series of imidazolidin-2-ones. The resulting oxazolidin-2-imines are among the most potent SARMs known, with many analogues exhibiting sub-nM in vitro potency in binding and functional assays. Despite the potential for hydrolytic instability at gut pH, compounds of the present class showed good oral bioavailability and were highly active in a standard rodent pharmacological model.


Journal of Medicinal Chemistry | 2016

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors

Peter W. Glunz; Luciano Mueller; Daniel L. Cheney; Vladimir Ladziata; Yan Zou; Nicholas R. Wurtz; Anzhi Wei; Pancras C. Wong; Ruth R. Wexler; E. Scott Priestley

Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.


Journal of Medicinal Chemistry | 2007

Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications

James J. Li; James C. Sutton; Alexandra A. Nirschl; Yan Zou; Haixia Wang; Chongqing Sun; Zulan Pi; Rebecca Johnson; Stanley R. Krystek; Ramakrishna Seethala; Rajasree Golla; Paul G. Sleph; Blake C. Beehler; Gary J. Grover; Aberra Fura; Viral Vyas; Cindy Y. Li; Jack Z. Gougoutas; Michael A. Galella; Robert Zahler; and Jacek Ostrowski; Lawrence G. Hamann


Bioorganic & Medicinal Chemistry Letters | 2007

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.

Lawrence G. Hamann; Mark C. Manfredi; Chongqing Sun; Stanley R. Krystek; Yanting Huang; Yingzhi Bi; David J. Augeri; Tammy C. Wang; Yan Zou; David A. Betebenner; Aberra Fura; Ramakrishna Seethala; Rajasree Golla; Joyce E. Kuhns; John A. Lupisella; Celia D'Arienzo; Laura Custer; Jennifer Price; James M. Johnson; Scott A. Biller; Robert Zahler; Jacek Ostrowski


Archive | 2006

Phenylglycinamide derivatives useful as anticoagulants

Xiaojun Zhang; Eldon Scott Priestley; Alexandra A. Nirschl; Yan Zou


Archive | 2006

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Xiaojun Zhang; Alexandra A. Nirschl; Yan Zou; Eldon Scott Priestley


Bioorganic & Medicinal Chemistry Letters | 2013

Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors.

Peter W. Glunz; Xiaojun Zhang; Yan Zou; Indawati Delucca; Alexandra H. Nirschl; Xuhong Cheng; Carolyn A. Weigelt; Daniel L. Cheney; Anzhi Wei; Rushith Anumula; Joseph M. Luettgen; Alan R. Rendina; Mark R. Harpel; Gang Luo; Robert M. Knabb; Pancras C. Wong; Ruth R. Wexler; E. Scott Priestley


Journal of Medicinal Chemistry | 2016

Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex

Xiaojun Zhang; Peter W. Glunz; James A. Johnson; Wen Jiang; Swanee Jacutin-Porte; Vladimir Ladziata; Yan Zou; Monique Phillips; Nicholas R. Wurtz; Brandon Parkhurst; Alan R. Rendina; Timothy M. Harper; Daniel L. Cheney; Joseph M. Luettgen; Pancras C. Wong; Dietmar A. Seiffert; Ruth R. Wexler; E. Scott Priestley


Archive | 2014

PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS

Peter W. Glunz; Yan Zou; Miami L. Quan; Vladimir Ladziata


Bioorganic & Medicinal Chemistry Letters | 2016

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Vladimir Ladziata; Peter W. Glunz; Yan Zou; Xiaojun Zhang; Wen Jiang; Swanee Jacutin-Porte; Daniel L. Cheney; Anzhi Wei; Joseph M. Luettgen; Timothy M. Harper; Pancras C. Wong; Dietmar Seiffert; Ruth R. Wexler; E. Scott Priestley

Collaboration


Dive into the Yan Zou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge